Furthermore, TRAIL resistant prostate cancer cells can be sensitised by AKTi co-treatment, which also prevents the TRAIL-induced induction of tumour promoting and pro-metastatic cytokines from the cancer cells, providing an added advantage. Here, TNFSF10 is linked to Familial prostate cancer.